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For many years, the heart failure community tracked the incidence of a first hospitalisation 
for heart failure (HF) as a marker of the “epidemic” of heart failure[1–3]. With the advent of 
better treatments for myocardial infarction, there was a fear that the consequence of more 
survivors with a damaged left ventricle would be a continuing rise in the number of people 
admitted to hospital for the first time with HF. The maturation of a number of health care 
record databases founded in the 1960s and 1970s allowed such epidemiological studies to 
be conducted. Indeed a rising incidence of HF hospitalisation was observed in many 
countries in the world until the mid-1990s[1–3]. However, at around the mid-1990s we 
started to see a decline in the incidence hospitalisations for HF[1–3]. The greater use of 
therapies to prevent the onset of HF, and the expanding treatment of HF, was thought 
underlie this reversal.  But these disease modifying treatments also brought with them 
improvements in survival with the consequence that there was an increase in the prevalence 
of heart failure and extension of the time a person lived with HF, thereby increasing the time 
at risk of further episodes of decompensation. Before the era of effective therapies, HF was 
a disease that killed very quickly (with a matter of months[4]) but since the introduction of 
ACE inhibitors/ARBs, beta-blockers and mineralocorticoid receptor antagonists, there has 
been a transition into a more chronic disease. While HF remains one of the most deadly CV 
diseases, patients with HF are readmitted multiple times for decompensation of their HF 
during the course of their lifetime[5]. The current problem therefore faced by many 
healthcare systems around the world is the issue of recurrent hospitalisations for heart 
failure. These admissions exert a tremendous burden on healthcare systems around the 
world and account for the majority of costs associated with HF[6]. Yet while we have multiple 
sources of evidence that incident HF hospitalisations have been declining less is known 
about patterns of recurrent HF hospitalisations. This is surprising given what we know about 
recurrent heart failure hospitalisations. They are a marker of poor prognosis, and the period 
following a hospitalisation is a particularly high-risk period for recurrent hospitalisation and 
death. In this edition of the journal Sulo et al [7] at all present an analysis of incident and 
total hospitalisations for heart failure in Norway between 2000 and 2014. The data from this 
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nationwide retrospective cohort study (which contains all hospital stays with a cardiovascular 
related diagnosis) confirm that there has been a continual decline in the incidence of first 
hospitalisation for heart failure. However, they also, and more importantly, report that there 
has been an increase in the risk of 30-day and 3-year readmissions for heart failure over this 
time. There was a 1.7% (95%CI 0.7-3%) per year increase in HF readmission rates at 30-
day readmission rates in men and 1.1% (95%CI -0.01 to 2.3%) in women. The risk of three-
year recurrent hospitalisation was similar while in-hospital mortality decreased in both men 
and women. Are these trends simply a reflection of making patients live longer and keeping 
them alive?  
 
We know from analyses of randomised trials that many of the therapies that we use to treat 
HF with reduced ejection fraction (HFREF) also reduce recurrent HF hospitalisations [8–11]. 
Therefore, why do we not see this translating into changes and epidemiological trends? 
There may be a number of factors at play. The changing demographics of patients with more 
comorbidities and older age could be one explanation, although the authors found similar 
trends in each age group. The perhaps more worrying potential explanation for this trend is 
that there has been a failure to use those therapies which have been shown to be effective 
in reducing the risk of recurrent HF hospitalisations. A consistent finding from HF registries 
around the world is the underuse of guideline recommended therapies for HF [12]. Finally, it 
may be a methodological issue with the database used by Sulo et a [7]l. They were unable 
to differentiate HFREF from HF with preserved ejection fraction (HFPEF) . No therapies 
have yeet been shown to be effective in HFPEF. Given that HFPEF is characterised by 
recurrent hospitalisations, more so than HFREF, therefore the growing burden of HFPEF 
could explain these trends.  
 
Perhaps counter intuitively, these trends could be viewed as a win for the heart failure 
community. Making patients survive longer will lead to a further prolongation of the period at 
which they are risk for a recurrent hospitalisation and consequently increasing the total 
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number of recurrent hospitalisations occurring which Sulo et al observed. If we are the 
victims of our own success, we must look at other ways to reduce the risk of HF 
hospitalisation. We can improve the use of medications and therapies shown to reduce the 
risk of HF hospitalisation. A more specific method may be to identify those patients at risk of 
hospitalisation or developing early signs of decompensation and intervening earlier through 
monitoring devices[13]. Finally an attractive option is reorganizing care to prevent hospital 
admissions. However, we must ask if this is actually solving the problem or shifting it 
somewhere else? After recognising the issue of rehospitalisation costs there has been a shift 
towards treating HF in outpatient setting. This may involve using therapies in the community 
that were previously used to treat HF in the hospital such as intravenous diuretics or to treat 
patients in special outpatient units. While this leads to some reduction in costs it must be 
recognised that these episodes of treatments for HF are as significant an event in the 
prognosis of the patient as the hospitalisation for HF[14]. The decompensation of a patient 
requiring treatment outpatient is associated with a higher risk of mortality, much the same as 
a hospitalisation for HF. Therefore, our ultimate aim should be a reduction in the episodes of 
decompensation, wherever they may be treated, rather than on hospitalisations per se. This 
will require further work to understand the epidemiology of these episodes of worsening HF 
in the community and will need our registries and databases to accurately collect information 
on these events. Analyses of trials of therapies for HFREF have demonstrated that these 
events can be modified and that it is important to do so given the prognosis they 
confer[14,15]. For the HF specialist practising today the best method of reversing these 
trends is still giving the patient all of the guideline recommended therapies that they are 
eligible for. However, to monitor our progress in preventing and treating HF we will have to 
expand our field of vision to capture all the potential HF events that occur, both in and out of 
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